{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,22]],"date-time":"2026-09-22T18:30:34Z","timestamp":1790101834090,"version":"4.0.1"},"reference-count":40,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2024,8,7]],"date-time":"2024-08-07T00:00:00Z","timestamp":1722988800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2024,8,7]],"date-time":"2024-08-07T00:00:00Z","timestamp":1722988800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"name":"Universitat de Valencia"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Pediatr Drugs"],"published-print":{"date-parts":[[2024,9]]},"DOI":"10.1007\/s40272-024-00647-5","type":"journal-article","created":{"date-parts":[[2024,8,7]],"date-time":"2024-08-07T14:02:52Z","timestamp":1723039372000},"page":"499-518","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["Comparison of Different Doses of Oral and Ocular Propranolol for Retinopathy of Prematurity: A Network Meta-Analysis"],"prefix":"10.1007","volume":"26","author":[{"given":"Amparo","family":"Ortiz-Seller","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pablo","family":"Martorell","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patricia","family":"Rosell\u00f3","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Esteban","family":"Morcillo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5130-9882","authenticated-orcid":false,"given":"Jos\u00e9 L.","family":"Ortiz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,8,7]]},"reference":[{"issue":"9902","key":"647_CR1","doi-asserted-by":"publisher","first-page":"1445","DOI":"10.1016\/S0140-6736(13)60178-6","volume":"382","author":"A Hellstr\u00f6m","year":"2013","unstructured":"Hellstr\u00f6m A, Smith LE, Dammann O. Retinopathy of prematurity. Lancet. 2013;382(9902):1445\u201357. https:\/\/doi.org\/10.1016\/S0140-6736(13)60178-6.","journal-title":"Lancet"},{"key":"647_CR2","doi-asserted-by":"publisher","DOI":"10.1007\/s00431-024-05450-5","author":"J Chen","year":"2024","unstructured":"Chen J, Zhu Y, Li L, Lv J, Li Z, Chen X, Chen X, Huang S, Xie R, Zhang Y, Ye G, Luo R, Shen X, Fu M, Zhuo Y. Visual impairment burden in retinopathy of prematurity: trends, inequalities, and improvement gaps. Eur J Pediatr. 2024. https:\/\/doi.org\/10.1007\/s00431-024-05450-5.","journal-title":"Eur J Pediatr"},{"issue":"3","key":"647_CR3","doi-asserted-by":"publisher","first-page":"279","DOI":"10.1016\/j.oret.2023.10.003","volume":"8","author":"SD Scarboro","year":"2024","unstructured":"Scarboro SD, Harper CA 3rd, Karsaliya G, Ghoraba H, Moshfeghi DM, Al-Khersan H, Robles-Holmes HK, Fan KC, Berrocal AM, Hoyek S, Patel NA, Sbrocca R, Capone A Jr, Drenser KA, Wood EH. The incidence and timing of treatment-requiring retinopathy of prematurity in nanopremature and micropremature infants in the United States: a national multicenter retrospective cohort study. Ophthalmol Retina. 2024;8(3):279\u201387. https:\/\/doi.org\/10.1016\/j.oret.2023.10.003.","journal-title":"Ophthalmol Retina"},{"issue":"2","key":"647_CR4","doi-asserted-by":"publisher","first-page":"148","DOI":"10.3390\/antiox13020148","volume":"13","author":"L Zhang","year":"2024","unstructured":"Zhang L, Buonfiglio F, Fiess A, Pfeiffer N, Gericke A. Retinopathy of prematurity-targeting hypoxic and redox signaling pathways. Antioxidants (Basel). 2024;13(2):148. https:\/\/doi.org\/10.3390\/antiox13020148.","journal-title":"Antioxidants (Basel)."},{"issue":"1","key":"647_CR5","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1055\/s-0040-1713181","volume":"39","author":"A Bancalari","year":"2022","unstructured":"Bancalari A, Schade R. Update in the treatment of retinopathy of prematurity. Am J Perinatol. 2022;39(1):22\u201330. https:\/\/doi.org\/10.1055\/s-0040-1713181.","journal-title":"Am J Perinatol"},{"key":"647_CR6","doi-asserted-by":"publisher","DOI":"10.1016\/j.preteyeres.2021.101018","volume":"88","author":"AS Tsai","year":"2022","unstructured":"Tsai AS, Chou HD, Ling XC, Al-Khaled T, Valikodath N, Cole E, Yap VL, Chiang MF, Chan RVP, Wu WC. Assessment and management of retinopathy of prematurity in the era of anti-vascular endothelial growth factor (VEGF). Prog Retin Eye Res. 2022;88: 101018. https:\/\/doi.org\/10.1016\/j.preteyeres.2021.101018.","journal-title":"Prog Retin Eye Res"},{"issue":"3","key":"647_CR7","doi-asserted-by":"publisher","first-page":"76","DOI":"10.1097\/00055735-199306000-00013","volume":"4","author":"JA McNamara","year":"1993","unstructured":"McNamara JA. Laser treatment for retinopathy of prematurity. Curr Opin Ophthalmol. 1993;4(3):76\u201380. https:\/\/doi.org\/10.1097\/00055735-199306000-00013.","journal-title":"Curr Opin Ophthalmol"},{"key":"647_CR8","doi-asserted-by":"publisher","DOI":"10.1016\/j.survophthal.2024.02.005","author":"A Ortiz-Seller","year":"2024","unstructured":"Ortiz-Seller A, Martorell P, Barranco H, Pascual-Camps I, Morcillo E, Ortiz JL. Comparison of different agents and doses of anti-vascular endothelial growth factors (aflibercept, bevacizumab, conbercept, ranibizumab) versus laser for retinopathy of prematurity: a network meta-analysis. Surv Ophthalmol. 2024. https:\/\/doi.org\/10.1016\/j.survophthal.2024.02.005.","journal-title":"Surv Ophthalmol"},{"issue":"4","key":"647_CR9","doi-asserted-by":"publisher","first-page":"328","DOI":"10.1016\/j.oret.2021.12.016","volume":"6","author":"C Zhang","year":"2022","unstructured":"Zhang C, Reynolds AL, Beiter A, Lillvis JH, Reynolds JD. Effect of low-dose intravitreal bevacizumab and ranibizumab on regression and late reactivation in retinopathy of prematurity in the treatment-naive eyes. Ophthalmol Retina. 2022;6(4):328\u201330. https:\/\/doi.org\/10.1016\/j.oret.2021.12.016.","journal-title":"Ophthalmol Retina"},{"issue":"3","key":"647_CR10","doi-asserted-by":"publisher","first-page":"1027","DOI":"10.1007\/s10792-022-02480-6","volume":"43","author":"GN Tsiropoulos","year":"2023","unstructured":"Tsiropoulos GN, Seliniotaki AK, Haidich AB, Ziakas N, Mataftsi A. Comparison of adverse events between intravitreal anti-VEGF and laser photocoagulation for treatment-requiring retinopathy of prematurity: a systematic review. Int Ophthalmol. 2023;43(3):1027\u201362. https:\/\/doi.org\/10.1007\/s10792-022-02480-6.","journal-title":"Int Ophthalmol"},{"issue":"1","key":"647_CR11","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1159\/000381659","volume":"108","author":"C B\u00fchrer","year":"2015","unstructured":"B\u00fchrer C, Bassler D. Oral propranolol: a new treatment for infants with retinopathy of prematurity? Neonatology. 2015;108(1):49\u201352. https:\/\/doi.org\/10.1159\/000381659.","journal-title":"Neonatology"},{"issue":"24","key":"647_CR12","doi-asserted-by":"publisher","first-page":"2649","DOI":"10.1056\/NEJMc0708819","volume":"358","author":"C L\u00e9aut\u00e9-Labr\u00e8ze","year":"2008","unstructured":"L\u00e9aut\u00e9-Labr\u00e8ze C, Dumas de la Roque E, Hubiche T, Boralevi F, Thambo JB, Ta\u00efeb A. Propranolol for severe hemangiomas of infancy. N Engl J Med. 2008;358(24):2649\u201351. https:\/\/doi.org\/10.1056\/NEJMc0708819.","journal-title":"N Engl J Med"},{"issue":"3","key":"647_CR13","doi-asserted-by":"publisher","first-page":"e484","DOI":"10.1542\/peds.2007-0803","volume":"123","author":"V Praveen","year":"2009","unstructured":"Praveen V, Vidavalur R, Rosenkrantz TS, Hussain N. Infantile hemangiomas and retinopathy of prematurity: possible association. Pediatrics. 2009;123(3):e484-489. https:\/\/doi.org\/10.1542\/peds.2007-0803.","journal-title":"Pediatrics"},{"key":"647_CR14","doi-asserted-by":"publisher","first-page":"1322783","DOI":"10.3389\/fped.2024.1322783","volume":"12","author":"F Pascarella","year":"2024","unstructured":"Pascarella F, Scaramuzzo RT, Pini A, Cammalleri M, Bagnoli P, Ciantelli M, Filippi L. Propranolol: a new pharmacologic approach to counter retinopathy of prematurity progression. Front Pediatr. 2024;12:1322783. https:\/\/doi.org\/10.3389\/fped.2024.1322783.","journal-title":"Front Pediatr"},{"key":"647_CR15","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2022.835771","volume":"13","author":"L Filippi","year":"2022","unstructured":"Filippi L, Cammalleri M, Amato R, Ciantelli M, Pini A, Bagnoli P, Dal Monte M. Decoupling oxygen tension from retinal vascularization as a new perspective for management of retinopathy of prematurity. New opportunities from beta-adrenoceptors. Front Pharmacol. 2022;13: 835771. https:\/\/doi.org\/10.3389\/fphar.2022.835771.","journal-title":"Front Pharmacol"},{"issue":"3","key":"647_CR16","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD011893.pub2","volume":"3","author":"S Kaempfen","year":"2018","unstructured":"Kaempfen S, Neumann RP, Jost K, Schulzke SM. Beta-blockers for prevention and treatment of retinopathy of prematurity in preterm infants. Cochrane Database Syst Rev. 2018;3(3): CD011893. https:\/\/doi.org\/10.1002\/14651858.CD011893.pub2.","journal-title":"Cochrane Database Syst Rev"},{"issue":"12","key":"647_CR17","doi-asserted-by":"publisher","first-page":"1584","DOI":"10.1038\/s41372-019-0503-x","volume":"39","author":"A Stritzke","year":"2019","unstructured":"Stritzke A, Kabra N, Kaur S, Robertson HL, Lodha A. Oral propranolol in prevention of severe retinopathy of prematurity: a systematic review and meta-analysis. J Perinatol. 2019;39(12):1584\u201394. https:\/\/doi.org\/10.1038\/s41372-019-0503-x.","journal-title":"J Perinatol"},{"key":"647_CR18","doi-asserted-by":"publisher","DOI":"10.3389\/fped.2021.631673","volume":"9","author":"HB Kong","year":"2021","unstructured":"Kong HB, Zheng GY, He BM, Zhang Y, Zhou Q. Clinical efficacy and safety of propranolol in the prevention and treatment of retinopathy of prematurity: a meta-analysis of randomized controlled trials. Front Pediatr. 2021;9: 631673. https:\/\/doi.org\/10.3389\/fped.2021.631673.","journal-title":"Front Pediatr"},{"key":"647_CR19","doi-asserted-by":"publisher","first-page":"141","DOI":"10.1016\/j.ajo.2023.11.012","volume":"259","author":"MA Shafique","year":"2024","unstructured":"Shafique MA, Haseeb A, Uddin MMN, Asghar B, Chaudhry ER, Raqib MA, Ali SMS, Mustafa MS. Effectiveness of propranolol in preventing severe retinopathy of prematurity: a comprehensive systematic review and meta-analysis. Am J Ophthalmol. 2024;259:141\u201350. https:\/\/doi.org\/10.1016\/j.ajo.2023.11.012.","journal-title":"Am J Ophthalmol"},{"issue":"11","key":"647_CR20","doi-asserted-by":"publisher","first-page":"777","DOI":"10.7326\/M14-2385","volume":"162","author":"B Hutton","year":"2015","unstructured":"Hutton B, Salanti G, Caldwell DM, Chaimani A, Schmid CH, Cameron C, Ioannidis JP, Straus S, Thorlund K, Jansen JP, Mulrow C, Catala-Lopez F, Gotzsche PC, Dickersin K, Boutron I, Altman DG, Moher D. The PRISMA extension statement for reporting of systematic reviews incorporating network meta-analyses of health care interventions: checklist and explanations. Ann Intern Med. 2015;162(11):777\u201384. https:\/\/doi.org\/10.7326\/M14-2385.","journal-title":"Ann Intern Med"},{"issue":"4","key":"647_CR21","doi-asserted-by":"publisher","first-page":"569","DOI":"10.1002\/jrsm.1373","volume":"10","author":"RK Owen","year":"2019","unstructured":"Owen RK, Bradbury N, Xin Y, Cooper N, Sutton A. MetaInsight: An interactive web-based tool for analyzing, interrogating, and visualizing network meta-analyses using R-shiny and netmeta. Res Synth Methods. 2019;10(4):569\u201381. https:\/\/doi.org\/10.1002\/jrsm.1373.","journal-title":"Res Synth Methods"},{"issue":"8","key":"647_CR22","doi-asserted-by":"publisher","first-page":"393","DOI":"10.1002\/psp4.12091","volume":"5","author":"D Mawdsley","year":"2016","unstructured":"Mawdsley D, Bennetts M, Dias S, Boucher M, Welton NJ. Model-based network meta-analysis: a framework for evidence synthesis of clinical trial data. CPT Pharmacometr Syst Pharmacol. 2016;5(8):393\u2013401. https:\/\/doi.org\/10.1002\/psp4.12091.","journal-title":"CPT Pharmacometr Syst Pharmacol"},{"key":"647_CR23","doi-asserted-by":"publisher","DOI":"10.1016\/j.arr.2022.101591","volume":"76","author":"D Gallardo-G\u00f3mez","year":"2022","unstructured":"Gallardo-G\u00f3mez D, Del Pozo-Cruz J, Noetel M, \u00c1lvarez-Barbosa F, Alfonso-Rosa RM, Del Pozo CB. Optimal dose and type of exercise to improve cognitive function in older adults: a systematic review and bayesian model-based network meta-analysis of RCTs. Ageing Res Rev. 2022;76: 101591. https:\/\/doi.org\/10.1016\/j.arr.2022.101591.","journal-title":"Ageing Res Rev"},{"key":"647_CR24","doi-asserted-by":"publisher","unstructured":"Pedder H. MBNMAdose: dose\u2013response model-based network meta-analysis. The comprehensive R archive network; 2022. https:\/\/doi.org\/10.5281\/zenodo.8221452","DOI":"10.5281\/zenodo.8221452"},{"issue":"5","key":"647_CR25","doi-asserted-by":"publisher","first-page":"F389","DOI":"10.1136\/archdischild-2016-311548","volume":"102","author":"KP Sanghvi","year":"2017","unstructured":"Sanghvi KP, Kabra NS, Padhi P, Singh U, Dash SK, Avasthi BS. Prophylactic propranolol for prevention of ROP and visual outcome at 1 year (PreROP trial). Arch Dis Child Fetal Neonatal Ed. 2017;102(5):F389\u201394. https:\/\/doi.org\/10.1136\/archdischild-2016-311548.","journal-title":"Arch Dis Child Fetal Neonatal Ed"},{"issue":"9","key":"647_CR26","doi-asserted-by":"publisher","first-page":"1921","DOI":"10.1007\/s10792-018-1018-8","volume":"39","author":"MA Ozturk","year":"2019","unstructured":"Ozturk MA, Korkmaz L. The efficacy of propranolol in very preterm infants at the risk of retinopathy of prematurity: which newborn and when? Int Ophthalmol. 2019;39(9):1921\u201330. https:\/\/doi.org\/10.1007\/s10792-018-1018-8.","journal-title":"Int Ophthalmol"},{"issue":"1","key":"647_CR27","doi-asserted-by":"publisher","first-page":"37","DOI":"10.18502\/wjpn.v2i1.2810","volume":"2","author":"A Mirjalili","year":"2019","unstructured":"Mirjalili A, Manaviat MR, Noori-Shadkam M. Evaluation of oral propranolol effect on retinopathy of prematurity: randomized clinical trial. World J Peri Neonatol. 2019;2(1):37\u201343. https:\/\/doi.org\/10.18502\/wjpn.v2i1.2810.","journal-title":"World J Peri Neonatol"},{"issue":"1","key":"647_CR28","doi-asserted-by":"publisher","first-page":"56","DOI":"10.34172\/cjmb.2022.10","volume":"9","author":"M Hosseini","year":"2022","unstructured":"Hosseini M, Gharebaghi MM, Bagheri M, Yeganehdoost S, Milani AE, Niyousha MR. Efficacy of oral propranolol on the treatment of retinopathy of prematurity. Crescent J Med Biol Sci. 2022;9(1):56\u201362. https:\/\/doi.org\/10.34172\/cjmb.2022.10.","journal-title":"Crescent J Med Biol Sci"},{"issue":"7","key":"647_CR29","doi-asserted-by":"publisher","first-page":"565","DOI":"10.1136\/archdischild-2013-303951","volume":"98","author":"IR Makhoul","year":"2013","unstructured":"Makhoul IR, Peleg O, Miller B, Bar-Oz B, Kochavi O, Mechoulam H, Mezer E, Ulanovsky I, Smolkin T, Yahalom C, Khoury A, Lorber A, Nir A, Blazer S. Oral propranolol versus placebo for retinopathy of prematurity: a pilot, randomised, double-blind prospective study. Arch Dis Child. 2013;98(7):565\u20137. https:\/\/doi.org\/10.1136\/archdischild-2013-303951.","journal-title":"Arch Dis Child"},{"issue":"1","key":"647_CR30","doi-asserted-by":"publisher","first-page":"88","DOI":"10.3109\/02713683.2016.1158272","volume":"42","author":"L Korkmaz","year":"2017","unstructured":"Korkmaz L, Ba\u015ftu\u011f O, Ozdemir A, Korkut S, Karaca C, Akin MA, Gunes T, Kurtoglu S, Ozturk MA. The Efficacy of propranolol in retinopathy of prematurity and its correlation with the platelet mass index. Curr Eye Res. 2017;42(1):88\u201397. https:\/\/doi.org\/10.3109\/02713683.2016.1158272.","journal-title":"Curr Eye Res"},{"key":"647_CR31","volume-title":"Treatment of retinopathy of prematurity with propranolol: a randomized control trial","author":"A Bancalari","year":"2018","unstructured":"Bancalari A. Treatment of retinopathy of prematurity with propranolol: a randomized control trial. Toronto, Canada: Pediatric Academic Sciences; 2018."},{"key":"647_CR32","first-page":"266","volume":"6","author":"H Sun","year":"2018","unstructured":"Sun H, Li M, Yu Z, Xing S, Yuan M, Cheng P. The efficacy and safety of oral propranolol in the treatment of retinopathy of prematurity. Chin J Neonatol. 2018;6:266\u201370.","journal-title":"Chin J Neonatol"},{"issue":"1","key":"647_CR33","doi-asserted-by":"publisher","first-page":"1","DOI":"10.22038\/ijn.2023.70115.2361","volume":"14","author":"P Mohammadi","year":"2023","unstructured":"Mohammadi P, Babaei H, Mohsenpour H, Azadi P. Efficacy of oral propranolol in prevention of severe retinopathy of prematurity: a randomized clinical trial study. Iran J Neonatol. 2023;14(1):1\u20137. https:\/\/doi.org\/10.22038\/ijn.2023.70115.2361.","journal-title":"Iran J Neonatol"},{"issue":"6","key":"647_CR34","doi-asserted-by":"publisher","first-page":"1570","DOI":"10.1016\/j.jpeds.2013.07.049","volume":"163","author":"L Filippi","year":"2013","unstructured":"Filippi L, Cavallaro G, Bagnoli P, Dal Monte M, Fiorini P, Donzelli G, Tinelli F, Araimo G, Cristofori G, La Marca G, Della Bona ML, La Torre A, Fortunato P, Furlanetto S, Osnaghi S, Mosca F. Oral propranolol for retinopathy of prematurity: risks, safety concerns, and perspectives. J Pediatr. 2013;163(6):1570-1577 e1576. https:\/\/doi.org\/10.1016\/j.jpeds.2013.07.049.","journal-title":"J Pediatr."},{"issue":"2","key":"647_CR35","doi-asserted-by":"publisher","first-page":"307","DOI":"10.1038\/pr.2016.230","volume":"81","author":"L Filippi","year":"2017","unstructured":"Filippi L, Cavallaro G, Bagnoli P, Dal Monte M, Fiorini P, Berti E, Padrini L, Donzelli G, Araimo G, Cristofori G, Fumagalli M, la Marca G, Della Bona ML, Pasqualetti R, Fortunato P, Osnaghi S, Tomasini B, Vanni M, Calvani AM, Milani S, Cortinovis I, Pugi A, Agosti M, Mosca F. Propranolol 0.1% eye micro-drops in newborns with retinopathy of prematurity: a pilot clinical trial. Pediatr Res. 2017;81(2):307\u201314. https:\/\/doi.org\/10.1038\/pr.2016.230.","journal-title":"Pediatr Res."},{"key":"647_CR36","doi-asserted-by":"publisher","first-page":"180","DOI":"10.3389\/fped.2019.00180","volume":"7","author":"L Filippi","year":"2019","unstructured":"Filippi L, Cavallaro G, Berti E, Padrini L, Araimo G, Regiroli G, Raffaeli G, Bozzetti V, Tagliabue P, Tomasini B, Mori A, Buonocore G, Agosti M, Bossi A, Chirico G, Aversa S, Fortunato P, Osnaghi S, Cavallotti B, Suzani M, Vanni M, Borsari G, Donati S, Nascimbeni G, Nardo D, Piermarocchi S, la Marca G, Forni G, Milani S, Cortinovis I, Calvani M, Bagnoli P, Dal Monte M, Calvani AM, Pugi A, Villamor E, Donzelli G, Mosca F. Propranolol 0.2% eye micro-drops for retinopathy of prematurity: a prospective phase IIB study. Front Pediatr. 2019;7:180. https:\/\/doi.org\/10.3389\/fped.2019.00180.","journal-title":"Front Pediatr"},{"issue":"9","key":"647_CR37","doi-asserted-by":"publisher","first-page":"1905","DOI":"10.1111\/apa.16850","volume":"112","author":"RT Scaramuzzo","year":"2023","unstructured":"Scaramuzzo RT, Bagnoli P, Dal Monte M, Cammalleri M, Pini A, Ballini S, Bendinelli A, Desideri I, Ciantelli M, Filippi L. Treating infants with 0.2% propranolol eye micro-drops drastically reduced the progression of retinopathy of prematurity. Acta Paediatr. 2023;112(9):1905\u20136. https:\/\/doi.org\/10.1111\/apa.16850.","journal-title":"Acta Paediatr"},{"issue":"5","key":"647_CR38","doi-asserted-by":"publisher","first-page":"499","DOI":"10.1515\/jpm-2015-0357","volume":"44","author":"A Bancalari","year":"2016","unstructured":"Bancalari A, Schade R, Munoz T, Lazcano C, Parada R, Pena R. Oral propranolol in early stages of retinopathy of prematurity. J Perinat Med. 2016;44(5):499\u2013503. https:\/\/doi.org\/10.1515\/jpm-2015-0357.","journal-title":"J Perinat Med"},{"issue":"1","key":"647_CR39","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1007\/s40272-021-00477-9","volume":"24","author":"C Colmant","year":"2022","unstructured":"Colmant C, Powell J. Medical management of infantile hemangiomas: an update. Paediatr Drugs. 2022;24(1):29\u201343. https:\/\/doi.org\/10.1007\/s40272-021-00477-9.","journal-title":"Paediatr Drugs"},{"issue":"1","key":"647_CR40","doi-asserted-by":"publisher","first-page":"16175","DOI":"10.1038\/s41598-023-43338-w","volume":"13","author":"P Murugeswari","year":"2023","unstructured":"Murugeswari P, Vinekar A, Prakalapakorn SG, Anandula VR, Subramani M, Vaidya TA, Nair AP, Jayadev C, Ghosh A, Kumaramanickavel G, Shetty R, Das D. Correlation between tear levels of vascular endothelial growth factor and vitamin D at retinopathy of prematurity stages in preterm infants. Sci Rep. 2023;13(1):16175. https:\/\/doi.org\/10.1038\/s41598-023-43338-w.","journal-title":"Sci Rep"}],"container-title":["Pediatric Drugs"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40272-024-00647-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40272-024-00647-5\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40272-024-00647-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,8,22]],"date-time":"2024-08-22T02:19:54Z","timestamp":1724293194000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40272-024-00647-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,8,7]]},"references-count":40,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2024,9]]}},"alternative-id":["647"],"URL":"https:\/\/doi.org\/10.1007\/s40272-024-00647-5","relation":{},"ISSN":["1174-5878","1179-2019"],"issn-type":[{"value":"1174-5878","type":"print"},{"value":"1179-2019","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,8,7]]},"assertion":[{"value":"24 July 2024","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 August 2024","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare that no funds, grants, or other financial support were received during the preparation of this manuscript.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Funding"}},{"value":"The authors (AO, PM, PR, EM, JLO) declare no financial or non-financial interests that are directly or indirectly related to this work.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of Interest"}},{"value":"Not applicable for meta-analyses.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics Approval"}},{"value":"Not applicable for meta-analyses.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to Participate"}},{"value":"Not applicable for meta-analyses.","order":6,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for Publication"}},{"value":"All data generated or analysed during this study are included in this published article and its supplementary information files.","order":7,"name":"Ethics","group":{"name":"EthicsHeading","label":"Availability of Data and Material"}},{"value":"Not applicable.","order":8,"name":"Ethics","group":{"name":"EthicsHeading","label":"Code Availability"}},{"value":"All authors contributed to the study conception and design. Methodology, software: JLO, AOS, PM. Material preparation and data acquisition: JLO, AOS. Data analysis and interpretation: JLO, AOS, EM, PR. First draft of manuscript: EM and JLO. All authors commented on the succeeding versions of the manuscript. All authors read and approved the final manuscript.","order":9,"name":"Ethics","group":{"name":"EthicsHeading","label":"Author Contributions"}}]}}